XOMA earnings analysis
What we found in XOMA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
XOMA's Q1 2026 results show a decrease in total revenues to $12.3 million from $15.9 million in the prior year, with gross margins remaining stable at 100%. However, net income improved significantly to $4.5 million compared to a loss of $1.2 million in Q1 2025, leading to an EPS of $0.18. The company continues to focus on its royalty aggregation strategy and anticipates future revenue growth from milestone and royalty payments.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth from VABYSMO and MIPLYFFA
- Revenues from VABYSMO increased to $11.9 million in Q1 2026, contributing to higher income from purchased receivables.
- Improved Net Income
- Net income reached $4.5 million in Q1 2026, compared to a loss of $1.2 million in Q1 2025.
- Operating Cash Flow Positive
- Operating cash flow increased to $6.1 million, a significant rise from $2.2 million in Q1 2025.
- Increased Cash Balances
- Cash and cash equivalents rose to $85.6 million from $82.9 million at the end of 2025.
- Successful Acquisition Strategy
- Completion of the Generation Bio acquisition for $34.4 million contributes strategic assets and expected future revenue.
- Gain on Acquisition
- A gain of $3.5 million was recognized from the Generation Bio acquisition.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Merger Completion Risks
- The pending merger with Ligand is subject to stockholder and regulatory approvals, with uncertainty around completion timing.
- Operational Uncertainties
- Uncertainties related to the achievement of milestones by partners, impacting future revenue from royalties.
- High Accumulated Deficit
- As of March 31, 2026, XOMA has an accumulated deficit of $1.2 billion, raising concerns about long-term sustainability.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.18
- Gross margin
- 100%
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads better than the one before it.
What came before.
- 10-K · March 18, 2026
- XOMA’s 2025 10-K positions the company as a royalty aggregator pursuing portfolio expansion through acquisitions and license transactions (multiple purchase/merger agreements listed in 2024–2025). Financially, revenue…
- 10-Q · August 13, 2025
- XOMA reported Q2 2025 total income and revenues of $13,129,000 and diluted EPS of $0.44. The company returned to operating profitability in the quarter with operating income of $4,603,000 versus an operating loss of…
- 10-Q · May 13, 2025
- XOMA reported a sharp top-line increase with total income and revenues of $15,912,000 in Q1 2025 (versus $1,490,000 in Q1 2024), producing operating income of $5,929,000 and diluted EPS of $0.06. The quarter was driven…
- 10-Q · November 7, 2024
- XOMA reported a strong top-line increase in Q3 2024 with total income and revenues of $7,197,000 versus $830,000 in Q3 2023, driven primarily by $6,463,000 of income from purchased receivables. However, operating losses…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing XOMA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever